UPADACITINIB AS MONOTHERAPY: A PHASE 3 RANDOMIZED CONTROLLED DOUBLE-BLIND STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE

被引：0

作者：

Smolen, J. S. ^{[1
]}

Cohen, S. ^{[2
]}

Emery, P. ^{[3
]}

Rigby, W. ^{[4
]}

Tanaka, Y. ^{[5
]}

Zhang, Y. ^{[6
]}

Friedman, A. ^{[6
]}

Othman, A. A. ^{[6
]}

Camp, H. S. ^{[6
]}

Pangan, A. L. ^{[6
]}

机构：

[1] Med Univ Vienna, Vienna, Austria

[2] Metroplex Clin Res Ctr, Dallas, TX USA

[3] Leeds NIHR BRC, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England

[4] Dartmouth Coll, Hanover, NH 03755 USA

[5] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka, Japan

[6] AbbVie, N Chicago, IL 60064 USA

来源：

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2019年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

223

引用

页码：S52 / S52

页数：1

共 50 条

[21] UPADACITINIB AS MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO METHOTREXATE: RESULTS AT 260 WEEKS FROM THE SELECT-MONOTHERAPY STUDY
Smolen, J. S.
Emery, P.
Rigby, W.
Tanaka, Y.
Vargas, J. Ignacio
Damjanov, N.
Jain, M.
Kato, K.
Carter, K.
Khan, N.
Camp, H.
Cohen, S. B.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 723 - 724
[22] UPADACITINIB AS MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO METHOTREXATE: RESULTS AT 84 WEEKS FROM THE SELECT-MONOTHERAPY STUDY
Smolen, J. S.
Emery, P.
Rigby, W.
Tanaka, Y.
Vargas, J. Ignacio
Damjanov, N.
Jain, M.
Song, Y.
Khan, N.
Enejosa, J. J.
Cohen, S. B.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 327 - 328
[23] A Phase 3, Randomized, Controlled Trial Comparing Upadacitinib Monotherapy to MTX Monotherapy in MTX-Naive Patients with Active Rheumatoid Arthritis
van Vollenhoven, Ronald
Takeuchi, Tsutomu
Pangan, Aileen L.
Friedman, Alan
Mohamed, Mohamed-Eslam
Chen, Su
Rischmueller, Maureen
Blanco, Ricardo
Xavier, Ricardo M.
Strand, Vibeke
[J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
[24] Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial
Genovese, Mark
Lertratanakul, Apinya
Anderson, Jaclyn K.
Papp, Kim
Tillett, William
Van den Bosch, Filip
Tsuji, Shigeyoshi
Dokoupilova, Eva
Keiserman, Mauro
Wang, Xin
Zhong, Sheng
Zueger, Patrick
Pangan, Aileen
Mease, Philip
[J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
[25] Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: An open-label extension of a randomized, double-blind, placebo-controlled trial
Hara, Masako
Ishiguro, Naoki
Katayama, Kou
Kondo, Masakazu
Sumida, Takayuki
Mimori, Tsuneyo
Soen, Satoshi
Nagai, Kota
Yamaguchi, Tomonobu
Yamamoto, Kazuhiko
[J]. MODERN RHEUMATOLOGY, 2014, 24 (03) : 410 - 418
[26] A PHASE 3 RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF UPADACITINIB (ABT-494), A SELECTIVE JAK-1 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DMARDS
Burmester, G.
Kremer, J.
van den Bosch, F.
Li, Y.
Zhou, Y.
Othman, A.
Pangan, A.
Camp, H.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 68 - 69
[27] A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate
Mease, P.
Strand, V.
Shalamberidze, L.
Dimic, A.
Raskina, T.
Xu, Li-An
Liu, Y.
Smith, J.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (07) : 1183 - 1189
[28] Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Study
Tanaka, Yoshiya
Takeuchi, Tsutomu
Yamanaka, Hisashi
Nanki, Toshihiro
Umehara, Hisanori
Yasuda, Nobuyuki
Tago, Fumitoshi
Kitahara, Yasumi
Kawakubo, Makoto
Torii, Kentaro
Hojo, Seiichiro
Kawano, Tetsu
Imai, Toshio
[J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 (04) : 587 - 595
[29] PRTX-100 and Methotrexate in Patients With Active Rheumatoid Arthritis: A Phase Ib Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study
Bernton, Edward
Gannon, William
Kramer, William
Kranz, Eduard
[J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014, 3 (06): : 477 - 486
[30] The Efficacy and Safety of Piclidenoson vs Methotrexate in Early Rheumatoid Arthritis: Phase 3 Randomized, Double-blind, Placebo-controlled Study
Reitblat, Tatiana
Gurman-Balbir, Alexandra
Harpaz, Zivit
Farbstein, Motti
Silverman, Michael
Kerns, William
Fishman, Pnina
[J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3564 - 3566

← 1 2 3 4 5 →